Coenzyme Q10 promotes osteoblast proliferation and differentiation and protects against ovariectomy-induced osteoporosis

Zheng,Delu; Cui,Chenli; Yu,Meng; Li,Xiang; Wang,Lu; Chen,Xinyan; Lin,Yichen

doi:10.3892/mmr.2017.7907

Coenzyme Q10 promotes osteoblast proliferation and differentiation and protects against ovariectomy-induced osteoporosis

Authors:
- Delu Zheng
- Chenli Cui
- Meng Yu
- Xiang Li
- Lu Wang
- Xinyan Chen
- Yichen Lin
View Affiliations

Affiliations: Department of Osteoporosis Diagnostic, Research and Treatment Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China, Department of Gynecology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China
Published online on: October 26, 2017 https://doi.org/10.3892/mmr.2017.7907
Pages: 400-407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Coenzyme Q10 (CoQ10) is a fat‑soluble vitamin‑like substance used for the treatment of a variety of disorders, including osteoporosis. The exact mechanism underlying CoQ10‑mediated protection against osteoporosis remains to be elucidated. The present study aimed to evaluate the effect of CoQ10 on osteoblastic cell proliferation and differentiation, and therapeutic effects on a rat model of osteoporosis. Following treatment with different concentrations of CoQ10, cell proliferation and differentiation of rat bone marrow stromal cells (BMSCs), and expression of osteoblastogenic markers, were measured. Rats with osteoporosis subjected to ovariectomy (OVX) were treated with different concentrations of CoQ10. Serum levels of estrogen and bone metabolism markers were measured. Micro computed tomography scans were used to analyze morphological changes in bones. In addition, mRNA and protein levels of phosphatidylinositol 3,4,5‑trisphosphate 3‑phosphatase and dual‑specificity protein phosphatase PTEN (PTEN)/phosphatidylinositol 4,5‑bisphosphate 3‑kinase (PI3K)/RAC‑alpha serine/threonine‑protein kinase(AKT), were determined. CoQ10 significantly increased the proliferation and osteogenic differentiation of BMSCs in a dose‑dependent manner, with an increased expression of osteogenic markers. CoQ10 significantly decreased bone resorption but exhibited no effect on serum E2 levels in vivo. CoQ10 markedly enhanced bone formation. Furthermore, the abundance of p‑PI3K and p‑AKT increased while PTEN levels decreased in a dose‑dependent manner following administration of CoQ10. CoQ10 stimulates the proliferation and differentiation of BMSCs and is effective for the treatment of OVX‑induced osteoporosis in rats. The above effects of CoQ10 may be mediated by activation of the PTEN/PI3K/AKT pathway.

View Figures

View References

1	Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
2	Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A and Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 22:465–475. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ray NF, Chan JK, Thamer M and Melton LJ III: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res. 12:24–35. 1997. View Article : Google Scholar : PubMed/NCBI
4	Qu B, Ma Y, Yan M, Wu HH, Fan L, Liao DF, Pan XM and Hong Z: The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int. 25:1853–1860. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis JA: Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 8:1362013. View Article : Google Scholar : PubMed/NCBI
6	Becker DJ, Kilgore ML and Morrisey MA: The societal burden of osteoporosis. Curr Rheumatol Rep. 12:186–191. 2010. View Article : Google Scholar : PubMed/NCBI
7	Groneberg DA, Kindermann B, Althammer M, Klapper M, Vormann J, Littarru GP and Döring F: Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int J Biochem Cell Biol. 37:1208–1218. 2005. View Article : Google Scholar : PubMed/NCBI
8	Linnane AW, Kios M and Vitetta L: Coenzyme Q(10)-its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion. 7 Suppl:S51–S61. 2007. View Article : Google Scholar : PubMed/NCBI
9	Littarru GP and Tiano L: Bioenergetic and antioxidant properties of coenzyme Q10: Recent developments. Mol Biotechnol. 37:31–37. 2007. View Article : Google Scholar : PubMed/NCBI
10	Jolliet P, Simon N, Barré J, Pons JY, Boukef M, Paniel BJ and Tillement JP: Plasma coenzyme Q10 concentrations in breast cancer: Prognosis and therapeutic consequences. Int J Clin Pharmacol Ther. 36:506–509. 1998.PubMed/NCBI
11	Moon HJ, Ko WK, Han SW, Kim DS, Hwang YS, Park HK and Kwon IK: Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun. 418:247–253. 2012. View Article : Google Scholar : PubMed/NCBI
12	Moon HJ, Ko WK, Jung MS, Kim JH, Lee WJ, Park KS, Heo JK, Bang JB and Kwon IK: Coenzyme q10 regulates osteoclast and osteoblast differentiation. J Food Sci. 78:H785–H891. 2013. View Article : Google Scholar : PubMed/NCBI
13	Panepucci RA, Siufi JL, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT and Zago MA: Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells. 22:1263–1278. 2004. View Article : Google Scholar : PubMed/NCBI
14	Yu H, VandeVord PJ, Mao L, Matthew HW, Wooley PH and Yang SY: Improved tissue-engineered bone regeneration by endothelial cell mediated vascularization. Biomaterials. 30:508–517. 2009. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Ke B, Xu Z, Ling Y, Qiu W, Xu Y, Higa T and Aruoma OI: Modulation of experimental osteoporosis in rats by the antioxidant beverage effective microorganism-X (EM-X). Biomed Pharmacother. 63:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
17	Laib A and Rüegsegger P: Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography. Bone. 24:35–39. 1999. View Article : Google Scholar : PubMed/NCBI
18	Eriksen EF, Díez-Pérez A and Boonen S: Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. Bone. 58:126–135. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fan JZ, Yang L, Meng GL, Lin YS, Wei BY, Fan J, Hu HM, Liu YW, Chen S, Zhang JK, et al: Estrogen improves the proliferation and differentiation of hBMSCs derived from postmenopausal osteoporosis through notch signaling pathway. Mol Cell Biochem. 392:85–93. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanly DA, McClung MR, Yuen CK and Kendler DL: Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 17:490–495. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ramalho-Ferreira G, Faverani L, Prado F, Garcia I and Okamoto R: Raloxifene enhances peri-implant bone healing in osteoporotic rats. Int J Oral Maxillofac Surg. 44:798–805. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lloyd M: Treatment of postmenopausal osteoporosis. N Engl J Med. 339:2021998. View Article : Google Scholar : PubMed/NCBI
23	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
24	Kendler D: Osteoporosis: Therapies now and in the future. Climacteric. 14:604–605. 2011.PubMed/NCBI
25	Caso G, Kelly P, McNurlan MA and Lawson WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 99:1409–1412. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lister RE: Coenzyme Q10 and periodontal disease. Br Dent J. 179:200–201. 1995. View Article : Google Scholar : PubMed/NCBI
27	Morisco C, Trimarco B and Condorelli M: Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study. Clin Investig. 71 8 Suppl:S134–S136. 1993. View Article : Google Scholar : PubMed/NCBI
28	Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
29	Tuli R, Tuli S, Nandi S, Wang ML, Alexander PG, Haleem-Smith H, Hozack WJ, Manner PA, Danielson KG and Tuan RS: Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells. 21:681–693. 2003. View Article : Google Scholar : PubMed/NCBI
30	Le Blanc K and Pittenger M: Mesenchymal stem cells: Progress toward promise. Cytotherapy. 7:36–45. 2005. View Article : Google Scholar : PubMed/NCBI
31	Neve A, Corrado A and Cantatore FP: Osteoblast physiology in normal and pathological conditions. Cell Tissue Res. 343:289–302. 2011. View Article : Google Scholar : PubMed/NCBI
32	Bhagavan HN and Chopra RK: Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 40:445–453. 2006. View Article : Google Scholar : PubMed/NCBI
33	Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT and Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 16:348–360. 2001. View Article : Google Scholar : PubMed/NCBI
34	Orimo H, Fujita T and Yoshikawa M: Increased sensitivity of bone to parathyroid hormone in ovariectomized rats. Endocrinology. 90:760–763. 1972. View Article : Google Scholar : PubMed/NCBI
35	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
36	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
37	Xi JC, Zang HY, Guo LX, Xue HB, Liu XD, Bai YB and Ma YZ: The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. J Recept Signal Transduct Res. 35:640–645. 2015. View Article : Google Scholar : PubMed/NCBI
38	Zhang Y, Zeng X, Zhang L and Zheng X: Stimulatory effect of puerarin on bone formation through activation of PI3K/Akt pathway in rat calvaria osteoblasts. Planta Med. 73:341–347. 2007. View Article : Google Scholar : PubMed/NCBI
39	Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ and Lim DS: Fibroblast growth factor-2 and −4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 17:725–736. 2008. View Article : Google Scholar : PubMed/NCBI
40	Choi H, Park HH, Koh SH, Choi NY, Yu HJ, Park J, Lee YJ and Lee KY: Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology. 33:85–90. 2012. View Article : Google Scholar : PubMed/NCBI